Department of AIDS Research, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
PLoS One. 2013 Aug 29;8(8):e72630. doi: 10.1371/journal.pone.0072630. eCollection 2013.
Assessing the prevalence of HIV-1 drug-resistance and the mutation patterns associated with resistance in the geographical regions implementing free antiretroviral therapy (ART) in China is necessary for preventing the spread of resistant strains and designing the regimens for the subsequent therapies with limited resources.
Plasma samples in different cities/prefectures were collected at Yunnan Provincial Hospital of Infectious Disease from January 2010 to December 2011. Genotyping of drug-resistant individuals was conducted using an in-house assay on plasma samples. Viral load, CD4 T cell counts and demographic data were obtained from medical records and an administered questionnaire.
A total of 609 pol sequences (515 ART-failure and 94 therapy-naïve individuals) derived from 664 samples were obtained. The prevalence of drug-resistance was 45.1% in the ART-failure individuals. Of these, 26.8% harbored HIV strains dually resistant to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors, and 14.8% harbored HIV strains resistant to only one drug category. Mutations such as M184V/I, K103N, V106A, Y181C and G190A were common among the ART-failure individuals, and the frequencies of M184V/I, K103N and V106A were 28.2%, 19.2%, and 22.1%, respectively. The percentages of individuals exhibiting intermediate or high-level resistance to 3TC, FTC, EFV and NVP drugs were 28.4%, 28.2%, 37.3%, and 37.5%, respectively. Factors such as ethnicity, transmission route, CD4 counts, viral load and the duration of ART were significantly correlated with development of drug resistance in the ART-failure individuals.
The high prevalence of HIV drug-resistance observed among the ART-failure individuals from 2010 to 2011 in Yunnan province should be of increasing concern in regions where the implementation of ART is widespread. Education about the risk factors associated with HIV drug resistance is important for preventing and controlling the spread of HIV drug-resistant strains.
在中国实施免费抗逆转录病毒治疗(ART)的地理区域,评估 HIV-1 耐药性的流行情况以及与耐药性相关的突变模式,对于防止耐药株的传播和设计后续治疗方案(资源有限)是必要的。
2010 年 1 月至 2011 年 12 月,从云南省传染病医院收集不同城市/县的血浆样本。使用基于血浆样本的内部测定法对耐药个体进行基因分型。从病历和管理的问卷中获得病毒载量、CD4 T 细胞计数和人口统计学数据。
共获得来自 664 个样本的 609 个 pol 序列(515 个 ART 失败和 94 个治疗初治个体)。ART 失败个体的耐药率为 45.1%。其中,26.8%的个体同时携带对核苷逆转录酶抑制剂和非核苷逆转录酶抑制剂双重耐药的 HIV 株,14.8%的个体携带仅对一种药物类别耐药的 HIV 株。M184V/I、K103N、V106A、Y181C 和 G190A 等突变在 ART 失败个体中较为常见,M184V/I、K103N 和 V106A 的频率分别为 28.2%、19.2%和 22.1%。对 3TC、FTC、EFV 和 NVP 药物表现出中高度耐药的个体比例分别为 28.4%、28.2%、37.3%和 37.5%。种族、传播途径、CD4 计数、病毒载量和 ART 持续时间等因素与 ART 失败个体的耐药发展显著相关。
2010 年至 2011 年在云南省,ART 失败个体中观察到的 HIV 耐药性高流行率应引起广泛实施 ART 的地区的日益关注。开展有关 HIV 耐药相关危险因素的教育,对于预防和控制 HIV 耐药株的传播非常重要。